Key Highlights

  • Daré Bioscience shares closed down 32% at $0.93.
  • The company announced the pricing of a $6.0 million registered direct offering at $1.37 per share.
  • The offering includes concurrent Series A and B warrants.
  • The Capital is intended to bolster the company's women's health development pipeline.

Daré Bioscience, Inc. (NASDAQ: DARE) shares closed down 32% at $0.93 after the company announced the pricing of a $6.0 million registered direct offering at $1.37 per share, including concurrent Series A and B warrants.

What Happened

The capital infusion is intended to bolster its women's health development pipeline while introducing notable Equity dilution for shareholders.

Market Reaction

Shares fell sharply as investors weighed the dilution implied by the offering, particularly the added potential dilution from the concurrent Series A and B warrants, against the extended capital available to fund the pipeline.

Outlook

The disclosed information does not include specific forward guidance beyond the completed offering; investors are likely to watch for further detail on how the proceeds are allocated across the company's women's health pipeline.